Finding the “Value” in Value-Based Health Care

Published Nov 6, 2017
Value-Based Health Care Examined from a Variety of Perspectives Glasgow, Scotland, UK—6 November 2017—ISPOR, the professional society for health economics and outcomes research (HEOR), opened its 20th Annual European Congress in Glasgow, Scotland, UK this morning with the first plenary session, “Where Is the Value in Value-Based Health Care?.” The plenary discussion was moderated by Maarten J. IJzerman, PhD, University of Twente, Enschede, The Netherlands. Speakers included Peter Naredi, University of Gothenburg and European CanCer Organization, Brussels, Belgium; Bettina Ryll, MD, PhD, Melanoma Patient Network Europe and European Society for Medical Oncology, Uppsala, Sweden; Jason Arora, MD, MPH, Medtronic, Watford, UK; and Luke Slawomirski, Organisation for Economic Co-operation and Development, Paris, France. Value-based health care approaches pricing of health care products and services in relation to the additional value they produce. Interest in value-based care has grown significantly as many health care practitioners and policy makers in European institutions now promote this approach as a more holistic, patient-centered understanding of value in health care. In this plenary session, speakers discussed the challenges and key differences of value-based health care compared with cost-effectiveness analysis, providing insights from a variety of perspectives, including clinicians, policy makers, patients, and manufacturers. Maarten J. IJzerman, PhD presented an overview of value-based health care noting that, “improving value is the only real solution.” He defined value as the set of outcomes that matter to a patient’s condition over the total cost of delivering those outcomes through the full cycle of care. Dr. IJzerman pointed out that the challenge in delivering value-based care is determining how to best design a health care delivery system that substantially improves patient value. Peter Naredi offered a clinician’s viewpoint and spoke about value-based cancer care sharing his experiences as a surgeon working in multidisciplinary teams. He pointed out that direct costs account for only half of total costs of care for a patient’s condition. Professor Naredi identified several “fast ways” to improve health care, including standardization and education, multidisciplinary care, and patient-centered care with informed patients involved in decisions. He stressed the importance of the multidisciplinary team approach in fulfilling the promise of value-based care. Bettina Ryll, MD, PhD provided the patient advocacy perspective and noted that while value-based health care promotes a patient-centered approach; the definition of “patient value” is not universally agreed upon. She pointed out that “value,” for example, can be seen very differently by a researcher compared to a patient living with a disease. Dr. Ryll discussed the issue of cost, noting that price is not cost. She stressed that health is an asset for society and not simply the absence of disease. Jason Arora, MD, MPH presented the manufacturer viewpoint and spoke about how value-based health care is transforming medical technology suppliers. He noted that health care faces a unique set of challenges: a) health care must be provided to everyone at some point in their lives, b) health care must be of high quality as health is a key enabler of everything we do, and c) health care must be provided with finite resources. Dr. Arora stated that a value-based approach to health care is prompting medtech suppliers to evolve into service providers.  Luke Slawomirski presented the policy maker perspective and examined the issue of value across a health care system. He noted that when assessing value it is important to look at the effects on populations over time. As an example, the value of curing hepatitis C in a patient impacts that patient’s life and the lives of other individuals who might have contracted the disease if that patient had not been cured. Mr. Slawomirski pointed out that for policy makers value is not just an equation; rather value is a way of thinking. Additional information on the ISPOR 20th Annual European Congress can be found here. Released presentations from the congress can be found here. Interested parties can follow news and developments from the congress on social media using the hashtag #ISPORGlasgow.

###

  ABOUT ISPOR ISPOR, the professional society for health economics and outcomes research (HEOR), is an international, multistakeholder, nonprofit dedicated to advancing HEOR excellence to improve decision making for health globally. The Society is the leading source for scientific conferences, peer-reviewed and MEDLINE-indexed publications, good practices guidance, education, collaboration, and tools/resources in the field. Web: www.ispor.org | LinkedIn: http://bit.ly/ISPOR-LIn | Twitter: http://bit.ly/ISPOR-T (@ISPORorg) | YouTube: http://bit.ly/ISPOR-YT | Facebook: http://bit.ly/ISPOR-FB

Related Stories

ISPOR Task Force Addresses Critical Gap in Surrogate Endpoint Guidance

May 28, 2026

Value in Health, announced the publication of an ISPOR Good Practices Report providing guidance on the use of surrogate endpoint evaluation methods in health technology assessment (HTA) decision making. The report, “Methods for Evaluation of Surrogate Endpoints for HTA Decision Making: A Good Practices Report of an ISPOR Task Force,” was published in the May 2026 issue of Value in Health.

How Is Health Valued in the United Kingdom? We Finally Have a Better Answer

May 27, 2026

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a pair of companion articles that together establish both the methodological foundation of the first definitive UK value set for the EQ-5D-5L and the practical implications of adopting it—thus equipping health technology assessment decision makers with a UK value set suitable for informing policy. The articles were featured in the May 2026 issue of Value in Health.

ISPOR Announces 2026-2027 Board of Directors

May 26, 2026

ISPOR—The Professional Society for Health Economics and Outcomes Research announced its 2026-2027 board of directors who will assume office on July 1, 2026.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×